UK-US Pharma Trade Deal | Tariff-Free Market Access
A new trade deal eliminates tariffs on pharmaceuticals between the UK and the US, strengthening transatlantic trade. This creates a powerful tailwind for pharmaceutical companies in both countries, potentially boosting exports, innovation, and profitability.
Your Basket's Financial Footprint
This basket's total market capitalisation is $813.93B. It is heavily anchored by several very large-cap stocks, which likely gives it a relatively stable, large-cap profile and closer tracking of broad-market moves.
- Large-cap dominance tends to lower volatility, offering more stable returns and closer tracking of broad-market moves.
- Suitable as a portfolio core holding rather than a speculative position, providing broad sector exposure.
- Likely to deliver steady, long-term appreciation rather than rapid, short-term gains.
GSK: $97.00B
AZN: $283.99B
BMY: $100.12B
- Other
About This Group of Stocks
Our Expert Thinking
The elimination of pharmaceutical tariffs between the UK and US creates a powerful financial tailwind for drugmakers in both countries. This landmark agreement reduces export costs, improves profit margins, and strengthens economic ties between two major economies. We've identified companies positioned to benefit from increased market access and streamlined trade flows.
What You Need to Know
This group includes major UK pharmaceutical exporters like GSK and AstraZeneca alongside leading US biotech firms. These companies stand to gain from reduced trade barriers, lower distribution costs, and enhanced collaboration opportunities. The deal addresses long-standing trade imbalances whilst boosting innovation potential on both sides of the Atlantic.
Why These Stocks
Each company was handpicked by professional analysts based on their strategic positioning to capitalise on this trade breakthrough. From established giants with significant cross-border operations to innovative biotech firms developing specialised treatments, these stocks represent the best opportunities to benefit from tariff-free pharmaceutical trade between the UK and US.
Why You'll Want to Watch These Stocks
Historic Trade Breakthrough
This is the first major pharmaceutical trade deal between the UK and US, creating unprecedented opportunities for companies on both sides of the Atlantic to boost profitability and market access.
Immediate Cost Savings
Tariff elimination means direct cost reductions for pharmaceutical exports, potentially improving profit margins for established players like GSK and AstraZeneca whilst opening new revenue streams.
Innovation Catalyst
Enhanced collaboration between UK and US biotech firms could accelerate drug development and research partnerships, particularly benefiting smaller clinical-stage companies in both markets.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Could Warsh's Fed Shift Fuel AI & Rate-Sensitive Stocks?
The nomination of Kevin Warsh as Federal Reserve Chair signals a potential shift toward lower interest rates driven by his belief in AI-fueled productivity. This basket highlights companies in rate-sensitive and high-growth sectors poised to benefit from cheaper borrowing costs.
LNP Patent Holders Shape Drug Delivery Value 2025
The massive settlement between Moderna and Arbutus/Genevant highlights the critical value of the lipid nanoparticle (LNP) technology used in mRNA vaccines. This creates a potential investment opportunity in companies that hold key patents for drug delivery systems, as they may be poised for lucrative licensing deals or acquisitions.
China AI Stocks: Could Alibaba's Exit Shift Power?
The sudden resignation of the head of Alibaba's AI division has created uncertainty around its ambitious AI strategy. This leadership vacuum could present a significant opportunity for the company's key competitors in China's rapidly growing AI sector.